Visit COVID-19 resources

[Skip to Content]

AMD

National Ophthalmology Database Funding boost for new UK AMD Audit

The Royal College of Ophthalmologists (RCOphth) is delighted to announce that the National Ophthalmology Database (NOD) Audit: Age-Related Macular Degeneration has now received funding for three years, enabling this important programme of long-term research and data gathering to begin. Age-related macular degeneration (AMD) remains a leading cause of sight impairment despite new treatment options. It

Martin McKibbin appointed Clinical Lead for the new AMD Audit

The Royal College of Ophthalmologists has committed to a three year project to develop an AMD national audit, supported by funding from the Macular Society for the first six months. We are delighted to announce Martin McKibbin, leading AMD specialist, St. James’s University Hospital, Leeds as Clinical Lead. Martin was the AMD lead for the

Be part of the new national AMD Audit Advisory Group – Open Call for applications

The Royal College of Ophthalmologists is calling for applications for membership of the new national Age Related Macular Degeneration (AMD) Audit Advisory Group. As an Advisory Group member, you will support the Clinical Lead, Martin McKibbin and project manager, Lynne Sanders, in developing the national AMD audit. The Advisory Group will work in partnership with

NICE publishes serious eye disorders quality standard

The Royal College of Ophthalmologists supports the quality standard but believes the implementation will be challenging for the overwhelmed hospital eye service.  The National Institute for Health and Care Excellence (NICE) has published its first quality standard looking at serious eye disorders, covering the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD)

New NICE Age Related Macular Degeneration guidance supports potential cost savings for the NHS

NHS Clinical Commissioners (NHSCC) and The Royal College of Ophthalmologists (RCOphth) welcome the publication today of guidance from the National Institute for Health and Care Excellence (NICE) which we believe can help to secure better value from the significant funds currently being spent on treating wet age related macular degeneration (AMD). In the current NHS